Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

22 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Sandostatin LAR Articles

Lotus to acquire gastric ulcer drug Yipubishan from Beijing Yipuam Bio

23 February 2009

Novartis drug slows 69% of GI tumors

26 January 2009

77% of patients on RAD001 achieve stable pancreatic NET tumors

22 September 2008

ESMO hears strong data on Novartis' everolimus in kidney cancer and NET tumors

22 September 2008

US FDA posts first quarterly report of potential safety issues, cites eight drugs

15 September 2008

Octreotide implant sees 6-month efficacy

10 December 2007

Expanded use for Novartis' Sandostatin LAR in UK

5 July 2004

Novartis' Sandostatin LAR OKed in Japan

3 May 2004

Novartis highlights clinical projects to turn around fortunes at its pharma

27 September 1999

Novartis Compares Growth Hormone Therapies

17 June 1999

Novartis highlights four new products at annual results meeting

18 March 1999

Novartis building on strong fundamentals, having achieved merger targets

16 March 1999

Novartis' Sandostatin LAR Depot Approved By FDA

2 December 1998

Novartis Files NDA For Sandostatin LAR

4 June 1998

Novartis Launches Sandostatin LAR In First Market

18 December 1997

Showing 1-15 of 15 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Is failure to adopt business process management putting the pharma industry at risk?
  • New Zealand declines Alexion's funding application for Solaris
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • Elan makes "transformational" acquisitions and a divestment
  • Is failure to adopt business process management putting the pharma industry at risk?
  • New Zealand declines Alexion's funding application for Solaris
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • Elan makes "transformational" acquisitions and a divestment

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS